IL6 and COVID-19: A total of 22 serum samples from patients with COVID-19 (2 mild, 10 moderate, and 10 severe) were used to longitudinally evaluate IL-6 enhancement at Days 1, 5, and 10 after diagnosis, which corresponded to 3, 7, and 12 days after the onset of symptoms, respectively (Figure 2).